Technical Analysis for GERN - Geron Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 3.75 | 1.77% | 0.07 |
GERN closed up 2.79 percent on Wednesday, April 17, 2024, on 71 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 1.77% | |
| Upper Bollinger Band Walk | Strength | 1.77% | |
| Upper Bollinger Band Touch | Strength | 1.77% | |
| 180 Bullish Setup | Bullish Swing Setup | 4.61% | |
| Inside Day | Range Contraction | 4.61% | |
| MACD Bearish Signal Line Cross | Bearish | 8.55% | |
| Slingshot Bullish | Bullish Swing Setup | 8.55% | |
| Upper Bollinger Band Touch | Strength | 8.55% | |
| New 52 Week High | Strength | 2.88% | |
| Above Upper BB | Strength | 2.88% |
| Alert | Time |
|---|---|
| Up 5% | about 3 hours ago |
| Rose Above Previous Day's High | about 4 hours ago |
| 60 Minute Opening Range Breakout | about 5 hours ago |
| Up 3% | about 5 hours ago |
| Down 1% | about 5 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Stem Cell Senescence Geron Corporation Haematopoiesis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Stem Cell Senescence Geron Corporation Haematopoiesis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.05 |
| 52 Week Low | 1.64 |
| Average Volume | 13,504,413 |
| 200-Day Moving Average | 2.37 |
| 50-Day Moving Average | 2.64 |
| 20-Day Moving Average | 3.38 |
| 10-Day Moving Average | 3.49 |
| Average True Range | 0.25 |
| RSI (14) | 66.10 |
| ADX | 50.18 |
| +DI | 35.68 |
| -DI | 10.24 |
| Chandelier Exit (Long, 3 ATRs) | 3.31 |
| Chandelier Exit (Short, 3 ATRs) | 3.74 |
| Upper Bollinger Bands | 3.72 |
| Lower Bollinger Band | 3.04 |
| Percent B (%b) | 0.94 |
| BandWidth | 20.34 |
| MACD Line | 0.28 |
| MACD Signal Line | 0.28 |
| MACD Histogram | -0.0066 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.94 | ||||
| Resistance 3 (R3) | 3.95 | 3.87 | 3.89 | ||
| Resistance 2 (R2) | 3.87 | 3.81 | 3.87 | 3.88 | |
| Resistance 1 (R1) | 3.78 | 3.77 | 3.83 | 3.77 | 3.86 |
| Pivot Point | 3.70 | 3.70 | 3.73 | 3.70 | 3.70 |
| Support 1 (S1) | 3.61 | 3.64 | 3.66 | 3.60 | 3.50 |
| Support 2 (S2) | 3.53 | 3.60 | 3.53 | 3.48 | |
| Support 3 (S3) | 3.44 | 3.53 | 3.47 | ||
| Support 4 (S4) | 3.43 |
